Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

NCT06736717 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Onvansertib
DRUG: NALIRIFOX

Sponsor

University of Kansas Medical Center

Collaborators

[object Object]